Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo
Authors:
- Xinhua LeeXLXinhua Lee
- Benxiu JiBJBenxiu Ji
- Kevin GuckianKGKevin Guckian
- Daniel ApiccoDADaniel Apicco
- R. Blake PepinskyRPR. Blake Pepinsky
- Robert H. MillerRMRobert H. Miller
- Sha MiSMSha Mi
- 1 September 2011
- journal article
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 48 (1) , 72-81
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P 1 ) modulationProceedings of the National Academy of Sciences, 2010
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosisNature Reviews Drug Discovery, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oligodendrocytes: biology and pathologyActa Neuropathologica, 2009
- Animal Models of Multiple Sclerosis2009
- Multiple sclerosisThe Lancet, 2008
- Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple SclerosisThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Toward the development of rational therapies in multiple sclerosis: what is on the horizon?Annals of Neurology, 2007
- Emerging oral therapies for multiple sclerosisInternational Journal Of Clinical Practice, 2007
- Sphingosine‐1‐phosphate induces proliferation and morphological changes of neural progenitor cellsJournal of Neurochemistry, 2004